ストックスクリーナーアプリを入手
43.53
1.00%
-0.44
アフターアワーズ：
43.53
Supernus Pharmaceuticals Inc (SUPN) 最新ニュース
Indivior stock gains on raised 2026 guidance and Supernus deal - AD HOC NEWS
Supernus Pharmaceuticals Inc. (SUPN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Supernus Pharmaceuticals to Participate in September Investor Conferences - Yahoo Finance
Chloe Kim will discuss her ADHD journey in Supernus partnership - Stock Titan
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - Barchart.com
Supernus Pharmaceuticals Inc. (SUPN) Peer Comparison – Compare with Others - Value Research
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Super - The National Law Review
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - FinancialContent
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock? - tradingview.com
A Look at Supernus Pharmaceuticals Inc (SUPN) After 3.4% Decline -- GF Value $43.78 vs Price $45.85 - GuruFocus
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Barchart.com
25,400 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Mystic Asset Management Inc. - MarketBeat
Indivior stock steadies after Supernus merger deal highlights $2.2 billion revenue goal - AD HOC NEWS
Supernus Pharmaceuticals (SUPN) Stock Looks Reasonable On Sales While Returns Look Strong - Sahm
Britannia, US WorldMeds, Supernus must face US Apokyn antitrust case, plaintiffs say - MLex
Supernus (SUPN) Results Review: The Available Earnings Metric Delivers a Beat in the Latest Reading; After Results: Shares Move 0.35% Lower in the Current UpdateGuidance Revision Trend - vinanet.vn
Supernus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SUPN) - TradingView
Indivior Q2 2026 Earnings Call: Complete Transcript - Sahm
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Sahm
Rice Hall James & Associates LLC Takes $22.80 Million Position in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by Bank of America Corp DE - MarketBeat
Details of Bhatt’s PSU Vesting and Tax Withholding at Supernus Pharmaceuticals - Kalkine Media
Supernus Pharmaceuticals CMO Jonathan Rubin Reports Vesting of 750 PSUs and Share Withholding for Taxes - Kalkine Media
Supernus Pharmaceuticals (SUPN) CEO exercises PSUs, withholds shares for taxes - Stock Titan
Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax - Stock Titan
Supernus Pharmaceuticals (SUPN) SVP converts 1,650 PSUs; 797 shares withheld for taxes - Stock Titan
Supernus Pharmaceuticals (SUPN) exec converts 2,500 PSUs, withholds shares for tax - Stock Titan
Supernus Pharmaceuticals, Inc.: Revenue and Earnings Analysts Forecasts Revisions | SUPN | US8684591089 - marketscreener.com
Supernus Pharmaceuticals CEO Jack A. Khattar Completes Vesting of Performance Share Units - Kalkine Media
Morgan Lewis Advises Supernus Pharmaceuticals on Merger with Indivior Pharmaceuticals – News - Morgan Lewis
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Why (SUPN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts - Yahoo Finance
Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc. - simplywall.st
Supernus Pharmaceuticals, Inc. (SUPN) Investor Outlook: A 31% Upside Potential Amid Strong Revenue Growth - DirectorsTalk Interviews
Supernus Pharmaceuticals (SUPN) Stock May Be A Bargain After Merger News - Yahoo Finance
Supernus Pharmaceuticals Inc. (S49.SG) Q2 FY2025 earnings call transcript - Yahoo Finance
Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
supernus pharmaceuticals, inc. Positive Earnings Pre-Announcements - RTTNews
Arrowstreet Capital Limited Partnership Trims Holdings in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Hold" at Wall Street Zen - MarketBeat
Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc.,M&A CallSlideshow - Seeking Alpha
Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders? - TradingView
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc.SUPN - marketscreener.com
New Strong Buy Stocks for August 7th - The Globe and Mail
Best Value Stocks to Buy for August 7th - The Globe and Mail
Millennium group (SUPN) reports Supernus stake falls below 5% ownership - Stock Titan
Rockville-Based Supernus and Indivior Agree to Merge, Creating a $2.2B CNS Powerhouse Headquartered in Maryland - BioBuzz
Rx Rundown: Supernus Pharmaceuticals, TCGX, Sandoz and more - Medical Marketing and Media
Q2 2026 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Supernus And Indivior To Merge And Create $2.2 Billion CNS Biopharmaceutical Company - Pulse 2.0
Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call High - GuruFocus
Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth ... - Yahoo! Finance Canada
Supernus Pharmaceuticals (NASDAQ:SUPN) Trading Down 6%Here's Why - MarketBeat
Supernus Pharmaceuticals Falls as Investors Weigh Newly Announced Indivior Merger Terms - moomoo.com
Supernus Pharmaceuticals falls as investors weigh newly announced Indivior merger terms - Quiver Quantitative
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Supernus and Indivior to Merge, Creating Diversified CNS Biopharma Company - Contract Pharma
$1.8bn merger unites Supernus and Indivior in CNS therapeutics play - BioXconomy
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook - Yahoo Finance
Supernus and Indivior merge to create scaled, CNS-focused entity - Yahoo Finance
Raleigh drug factory part of $2B merger - The Business Journals
Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Navigating A 38% Potential Upside - DirectorsTalk Interviews
Supernus Pharmaceuticals and Indivior Reveal All-Stock Merger of Equals Deal - Kalkine Media
1.66%
0.33%
大文字化:
|
ボリューム (24 時間):